# Self-Review Comments — Demo 3: NHANES Obesity & Diabetes

Generated: 2026-04-14
Guideline: STROBE
Verdict: **REVISE** (Score: 75/100)
Fatal flags: 0

## Score Breakdown

| Category | Weight | Score | Max |
|----------|--------|-------|-----|
| A. Study Design & Validity | 20% | 14 | 20 |
| B. Statistical Methodology | 25% | 21 | 25 |
| C. Results Completeness | 20% | 16 | 20 |
| D. Discussion & Novelty | 15% | 10 | 15 |
| E. Methods Transparency | 10% | 8 | 10 |
| F. References & Reporting | 10% | 6 | 10 |
| **Total** | **100%** | **75** | **100** |

## Major Issues

| ID | Category | Issue |
|----|----------|-------|
| M1 | A | **Cross-sectional design limits causal inference.** Acknowledged in limitations, but the title and portions of the discussion could be read as implying causality. The phrase "obesity was associated with a fourfold increase" is appropriately worded, but some sentences in the abstract and discussion could be strengthened with explicit causal caveats. |
| M2 | B | **Complex survey variance estimation not used.** The frequency-weight normalization approach preserves point estimates but does not account for stratification and clustering in variance estimation. Taylor series linearization or BRR should be used for NHANES analyses. This is acknowledged as a limitation but represents a genuine methodological shortcoming. |
| M3 | A | **Diabetes defined by HbA1c alone.** Self-reported diabetes, fasting glucose, and medication use are available in NHANES but not used. This likely underestimates true diabetes prevalence (misses controlled patients). |
| M4 | D | **Limited novelty.** The obesity-diabetes association in NHANES is extensively documented. The manuscript does not clearly articulate what this analysis adds to the 2017-2018 cycle specifically, beyond updating known associations. |

## Minor Issues

| ID | Category | Issue |
|----|----------|-------|
| m1 | F | **Unverified references (5 items).** All references marked [UNVERIFIED - DEMO]. |
| m2 | B | **Missing data approach not explicitly stated.** Complete-case analysis is implied but should be stated. The proportion excluded due to missing data should be reported alongside potential selection bias. |
| m3 | C | **No sensitivity analysis for diabetes definition.** An alternate definition including fasting glucose >= 126 or self-reported diabetes could test robustness. |
| m4 | A | **Underweight exclusion rationale.** The exclusion of 74 underweight participants is reasonable but the clinical rationale should be stated (e.g., reverse causation from illness-related weight loss). |
| m5 | D | **Asian-specific BMI thresholds not analyzed.** The Discussion notes that Asian populations develop metabolic complications at lower BMI thresholds, but the analysis uses standard WHO cut-points. A sensitivity analysis with Asian-specific cut-points would strengthen this finding. |

## Strengths

1. Nationally representative dataset with adequate sample size (n = 4,866) for stable multivariable estimates.
2. Both unadjusted and adjusted models reported, demonstrating confounding direction and magnitude.
3. Survey weights incorporated, even if variance estimation is simplified.
4. Clear dose-response pattern across three BMI categories.
5. Subgroup analysis by age × BMI reveals clinically meaningful interaction (32.4% prevalence in obese 60-79 year-olds).
